Neumarker Inc.
Neumarker's mission is to develop reliable, actionable, and objective biomarkers for precision neuromedicine, aiming to assist mental health clinicians, support CNS drug developers, and provide hope to patients suffering from CNS diseases. The company addresses the significant global burden of CNS disorders like Alzheimer's, depression, and schizophrenia, which are often treated ineffectively through trial-and-error, leading to prolonged patient distress and high healthcare costs. Neumarker leverages AI to decode brain functions and uncover key biomarkers that identify pathological conditions and treatment responses. This technology aims to transform the understanding and treatment of CNS diseases by enabling personalized treatment plans and accelerating drug development through efficient clinical trials. Neumarker is committed to advancing precision neuromedicine through collaborations with drug developers, clinicians, and academic researchers.
Neumarker Inc.
Neumarker's mission is to develop reliable, actionable, and objective biomarkers for precision neuromedicine, aiming to assist mental health clinicians, support CNS drug developers, and provide hope to patients suffering from CNS diseases. The company addresses the significant global burden of CNS disorders like Alzheimer's, depression, and schizophrenia, which are often treated ineffectively through trial-and-error, leading to prolonged patient distress and high healthcare costs. Neumarker leverages AI to decode brain functions and uncover key biomarkers that identify pathological conditions and treatment responses. This technology aims to transform the understanding and treatment of CNS diseases by enabling personalized treatment plans and accelerating drug development through efficient clinical trials. Neumarker is committed to advancing precision neuromedicine through collaborations with drug developers, clinicians, and academic researchers.